Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Xeloda + Irinotecan in Advanced Colorectal Cancer
NCT00048126Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2001
- Primary completion
- Jan 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in colorectal cancer (CRC), sponsored by Roche. Primary endpoint: Objective Response Rate. Started Jul 2001; status: completed.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00048126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048126.